NeOnc Technologies showcased updated clinical data for two brain cancer drugs, intranasal NEO100 and oral NEO212, at the Society for Neuro-Oncology meeting. NEO100 showed durable remission and prolonged survival in difficult-to-treat astrocytoma patients with no severe side effects, supporting a potential accelerated FDA approval. NEO212 demonstrated safety and early activity in temozolomide-resistant glioblastoma and brain metastases, with patients responding well over 20 months. Upcoming FDA meetings in late 2026 and early 2027 will discuss approval pathways and trial designs, while insider buying and international collaborations add investor interest.
NeOnc Technologies' brain cancer drug programs provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 20:42 WIB: of 150 priced health-sector US stocks, 107 rose and 39 fell. Notable movers include AHCO at USD 7.68 with a 2.41% decline and 100% sell order activity, ABCL at USD 11.87 gaining 2.15% with 79% buy order activity, and COO at USD 63.52 up 2.14%, with a typical hold time of 12 days.
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
